Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)
2019637 citationsBrian T. Tsuji, Jason M. Pogue et al.Pharmacotherapy The Journal of Human Pharmacology and Drug Therapyprofile →
Author Peers
Peers are selected by citation overlap in the author's most active subfields.
citations ·
hero ref
This map shows the geographic impact of Donald Kaye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donald Kaye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donald Kaye more than expected).
This network shows the impact of papers produced by Donald Kaye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donald Kaye. The network helps show where Donald Kaye may publish in the future.
Co-authorship network of co-authors of Donald Kaye
This figure shows the co-authorship network connecting the top 25 collaborators of Donald Kaye.
A scholar is included among the top collaborators of Donald Kaye based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Donald Kaye. Donald Kaye is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
20 of 20 papers shown
1.
Kaye, Donald. (2020). How Korea Trounced United States in Race to Test People for Coronavirus. Clinical Infectious Diseases. 71(1).1 indexed citations
2.
Tsuji, Brian T., Jason M. Pogue, Alexandre Prehn Zavascki, et al.. (2019). International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 39(1). 10–39.637 indexed citations breakdown →
Kaye, Donald. (1975). Host defense mechanisms in the urinary tract.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 2(3). 407–22.29 indexed citations
12.
Cox, C. E. & Donald Kaye. (1973). Symposium on oral indanyl carbenicillin in the treatment of urinary-tract infection. Tulane University School of Medicine, New Orleans, Louisiana. June 6, 1972.. The Journal of Infectious Diseases. 127.2 indexed citations
Kaye, Donald, et al.. (1965). Preliminary observations on the possible advantages of butterfat in cooking.. New Zealand Journal of Science. 8. 144–148.1 indexed citations
19.
Kaye, Donald, et al.. (1964). THE TYPHOID CARRIER STATE: QUANTITATIVE BACTERIOLOGY AND PRELIMINARY OBSERVATIONS ON THERAPY.. PubMed. 41. 219–27.9 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.